Exciting New Developments at Bioretec Ltd Regarding Shares

Author: Thomas Cooper Updated: 05-20-2025 07:44 AM

Bioretec Ltd Announces Registration of New Shares

Bioretec Ltd has successfully registered a sum of 60,000 new shares following subscriptions made through its option rights program. This milestone reflects the company's progress and strategic direction toward enhancing its operations and shareholder value.

Details of the New Share Subscription

The new shares, part of option program 2018-1A, have been officially entered into the trade register at the Finnish Patent and Registration Office. The total subscription price amounts to EUR 90,000, which will contribute to Bioretec's reserve of unrestricted equity, while keeping the company's share capital stable.

Implications of the New Shares

Including these new shares, Bioretec Ltd now has a total of 24,626,474 shares in circulation. The issuance will occur in the book-entry system soon, enhancing the trading landscape for investors. The commencement of trading for these new shares is anticipated on Nasdaq First North Growth Market Finland.

Contact Information for Further Inquiries

For additional information or queries related to this announcement, you may contact:
Sarah van Hellenberg Hubar-Fisher, Interim CEO, +31 6 1544 8736
Johanna Salko, CFO, +358 40 754 8172

Certified Advisor Contacts

Nordic Certified Adviser AB can be reached for venture advisement at +46 70 551 67 29.

About Bioretec Ltd

Bioretec is a forward-thinking Finnish medical device company renowned for its pioneering work in the field of biodegradable orthopedic implants. Focusing on biological interfaces of active implants, Bioretec enhances bone regeneration and accelerates healing after orthopedic surgeries, demonstrating a commitment to innovation.

The company is currently advancing its RemeOs™ product line, which utilizes magnesium alloys and hybrid composites, signifying a new evolution in biodegradable materials designed for better surgical outcomes. These implants are absorbed and converted by the body as healing progresses, negating the necessity for surgical removal and streamlining patient recovery processes. This ground-breaking approach has the potential to render traditional titanium implants obsolete, significantly contributing to Value-Based Healthcare by optimizing patient care efficiency.

Bioretec has achieved significant milestones, including receiving market authorization for its first RemeOs™ product in the U.S. in early 2023 and obtaining CE mark approval in Europe as recently as January 2025. Positioned strategically, the company is targeting the expansive over USD 9 billion global orthopedic trauma and spine market, aiming to revolutionize bone fracture treatments.

Frequently Asked Questions

What recent developments have occurred at Bioretec Ltd?

Bioretec Ltd has registered 60,000 new shares as part of its option rights program, reinforcing its commitment to growth and shareholder value.

How many shares does Bioretec have in total now?

With the new shares included, Bioretec Ltd has a total of 24,626,474 shares active in the market.

Where will the new shares be traded?

The new shares are expected to start trading on Nasdaq First North Growth Market Finland.

Who can I contact for more information about Bioretec?

You can reach Sarah van Hellenberg Hubar-Fisher or Johanna Salko for any inquiries regarding the company.

What is the focus of Bioretec's product development?

Bioretec is focused on developing biodegradable orthopedic implants that enhance bone healing and eliminate the need for removal surgeries.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.